GlassScriptPhysician profile
Francis Barber
NPI 1518965011
$912.57
in general payments reported to CMS, 2019-2025
13 companies · $233 in 2025
The $233 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $142 · 2020: $11.34 · 2021: $55.67 · 2022: $114 · 2023: $121 · 2024: $236 · 2025: $233.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $506 · Education: $82.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $506.38 |
| Education | $82.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $338.30 | 2019-2025 | Tremfya |
| Abbvie INC. | $178.53 | 2024 | |
| Sun Pharmaceutical Industries INC. | $82.95 | 2023 | |
| Genzyme Corporation | $71.79 | 2022-2025 | |
| Almirall LLC | $54.55 | 2019-2022 | |
| Incyte Corporation | $44.34 | 2022-2024 | Opzelura |
| Pfizer INC. | $34.64 | 2022-2024 | |
| E.R. Squibb & Sons, L.L.C. | $33.32 | 2023-2024 | Sotyktu |
| Journey Medical Corporation | $20.06 | 2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $15.39 | 2023 | Jublia, Arazlo |
| Sanofi-Aventis U.S. LLC | $15.18 | 2021 | |
| Ucb, INC. | $14.77 | 2025 | Bimzelx |
| Biofrontera INC. | $8.75 | 2023 | Xepi, Bf-Rhodoled, Ameluz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Francis Barber listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.